Claims
- 1. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 2. The method according to claim 1, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 3. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 4. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 5. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 6. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 7. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 8. The method according to claim 1, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 9. The method according to claim 2, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the fort of an aerosol formulation.
- 10. The method according to claim 2, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 11. The method according to claim 2, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 12. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 13. The method according to claim 12, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 14. The method according to claim 12, wherein the (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 15. The method according to claim 12, wherein the (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 16. The method according to claim 12, wherein the (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 17. The method according to claim 12, wherein the (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 18. The method according to claim 12, wherein the (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 19. The method according to claim 12, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 20. The method according to claim 13, wherein the (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 21. The method according to claim 13, wherein the (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 22. The method according to claim 13, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 23. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 24. The method according to claim 23, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 25. The method according to claim 23, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 26. The method according to claim 23, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 27. The method according to claim 23, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 28. The method according to claim 23, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 29. The method according to claim 23, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 30. The method according to claim 23, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 31. The method according to claim 24, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 32. The method according to claim 24, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 33. The method according to claim 24, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 34. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 35. The method according to claim 34, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 36. The method according to claim 34, wherein the (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 37. The method according to claim 34, wherein the (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 38. The method according to claim 34, wherein the (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 39. The method according to claim 34, wherein the (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 40. The method according to claim 34, wherein the (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 41. The method according to claim 34, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 42. The method according to claim 35, wherein the (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 43. The method according to claim 35, wherein the (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 44. The method according to claim 35, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 45. A method of treatment of spasms of smooth muscles by administration of a pharmaceutically suitable salt of an enantiomerically enriched ester selected from the group consisting of
(3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, ((3S,2′R)-)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, and (3S,2′R)--3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 46. The method according to claim 45, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 47. The method according to claim 45, wherein said ester has an enantiomeric purity of minimum 96% enantiomeric excess.
- 48. The method according to claim 45, wherein said ester has an enantiomeric purity of minimum 97% enantiomeric excess.
- 49. The method according to claim 45, wherein said ester has an enantiomeric purity of minimum 98% enantiomeric excess.
- 50. The method according to claim 45, wherein said ester is (3R,2 R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 51. The method according to claim 45, wherein said ester is (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 52. The method according to claim 45, wherein said ester is (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 53. The method according to claim 45, wherein said ester is (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 54. The method according to claim 45, wherein said salt is administered by inhalation.
- 55. The method according to claim 45, wherein said salt is administered by inhalation of an aerosol formulation.
- 56. The method according to claim 45, wherein said salt is administered by inhalation of a dry powder formulation.
- 57. The method according to claim 46, wherein said salt is administered by inhalation of an aerosol formulation.
- 58. The method according to claim 46, wherein said salt is administered by inhalation of a dry powder formulation.
Priority Claims (2)
Number |
Date |
Country |
Kind |
A 1973/96 |
Nov 1996 |
AT |
|
PCT/AT97/00245 |
Nov 1997 |
AT |
|
CROSS REFERENCE TO RELATED APPLICATION
[0001] This is a continuation-in-part of application Ser. No. 09/309,960, filed on May 11, 1999.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09309960 |
May 1999 |
US |
Child |
09901217 |
Jul 2001 |
US |